Product Pipeline
Focused on Innovation
CSL is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma protein technology, recombinant protein technology, cell and gene therapy and vaccines technology to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in five Therapeutic Areas - Immunoglobulins, Hematology, Cardiovascular & Renal, Transplant & Immunology and Vaccines. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth.
Core Capabilities
as demonstrated in our product pipeline
Phase I
Phase II
Phase III
Registration / Post-Registration
Anumigilimab Anti-G-CSFR mAb (SCD)
CSL040 Complement R1 Inhibitor
A recombinant glycoprotein which inhibits the classical, lectin and alternative Complement pathways for the potential treatment of acute indications involving Complement‐mediated tissue damage and inflammation.
CSL405 Cell-based Influenza (H2N3) Vaccine
For protection against Pandemic Influenza A (H2N3)
CSL406 sa-mRNA Influenza (H5N1) Vaccine
For protection against Pandemic Influenza A (H5N1).
CSL400 (TIV) sa-mRNA Trivalent Influenza Vaccine
LASN01 Anti-IL-11R mAb (IPF, TED)
Humanized recombinant monoclonal antibody targeting interleukin-11 (IL-11) for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF) and Thyroid Eye Disease (TED).
*Licensed to Lassen Therapeutics.
Horizon 2 Ig Yield
CSL787 Nebulised Ig
Human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Non-Cystic Fibrosis Bronchiectasis (NCFB).
Hemopexin (VOC in SCD)
Plasma-derived hemopexin for potential treatment of acute Vascular Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) patients.
Vamifeport Ferroportin inhibitor (HH)
CSL301 Anti-α2AP mAb (sPE)*
Anti-α2-antiplasmin monoclonal antibody, which is being developed to dissolve thrombi that cause serious conditions such as submassive pulmonary embolism (sPE) and acute ischemic stroke (AIS).
CSL525 (SNF472) Calcification inhibitor (CUA-ESKD)
Calcification inhibitor for treatment of calcific uremic arteriolopathy (CUA) in patients with end-stage kidney disease (ESKD).
Eblasakimab (CSL334) Anti-IL-13R mAb (AD)
Monoclonal antibody targeting IL-13Rα1 for the treatment of atopic dermatitis (AD) and asthma.
*Licensed to ASLAN Pharmaceuticals.
HIZENTRA® (SCIg) 20% Liquid
(CLL)
HIZENTRA® (SClg) 20% Liquid (POTS)
20% subcutaneous immunoglobulin for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM).
RiaSTAP® Fibrinogen Concentrate (AFD)
Clazakizumab Anti-IL-6 mAb
Clazakizumab (an anti-IL6 antibody) for the prevention of cardiovascular morbidity and mortality in patients with end-stage kidney disease
CSL964 Alpha 1 Antitrypsin (Treatment of aGvHD)*
Treatment of steroid refractory, acute Graft-versus-Host Disease (aGvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).
CSL964 Alpha 1 Antitrypsin (Prevention of aGvHD)
Prevention of acute Graft-versus-Host Disease (aGvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).
FLUAD® Trivalent Efficacy Adjuvanted Egg-based Influenza Vaccine
CSL403 (aTIVc) Adjuvanted Cell-based Trivalent Influenza Vaccine
Trivalent Seasonal Influenza Vaccine (Adjuvanted; Cell-based). High dose vaccine offering protection against different influenza virus strains.
HIZENTRA® (SCIg) 20% Liquid
20% subcutaneous immunoglobulin for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM).
PRIVIGEN® (IVIg) 10% Liquid
10% intravenous immunoglobulin.
ZEMAIRA®/RESPREEZA® Alpha 1 Antitrypsin
Human Alpha 1 Antitrypsin (AAT) (Plasma); To slow the progression of emphysema caused by Alpha 1 Antitrypsin Deficiency (AATD).
HAEGARDA® C1 Inhibitor (HAE)
Subcutaneous C1 Esterase Inhibitor (C1-INH) (Plasma), prophylaxis therapy for Hereditary Angioedema (HAE) attacks.
Garadacimab Anti-FXIIa mAb (HAE)
Humanised anti-factor XIIa monoclonal antibody for the potential treatment of Hereditary Angioedema (HAE) by subcutaneous administration.
AFSTYLA® rFVIII (Haem A)
Novel, recombinant factor VIII product for the treatment of adults and children with hemophilia A.
IDELVION® rFIX-FP (Haem B)
Novel, long-acting recombinant factor IX product for the treatment of hemophilia B.
HEMGENIX® (Haem B)
Adeno-associated virus vector-based gene therapy indicated for treatment of adults with Hemophilia B (congenital Factor IX deficiency).
FILSPARI® (Sparsentan) Dual ETA
& AT1 antagonist (IgAN)*
Oral, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist (DEARA) with high selectivity for the ETAR and AT1R for treatment of immunoglobulin A nephropathy (IgAN).
KORSUVA®/KAPRUVIA® KOR. agonist (CKD-aP)*
Difelikefalin - a kappa-opioid receptor (KOR) agonist for treatment of moderate-to-severe pruritus associated with CKD in adult patients on haemodialysis.
RAYALDEE® Oral ext. release calcifediol (SHPT)*
Orally administered, prolonged-release formulation of calcifediol for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency or deficiency.
TAVNEOS® Oral C5a receptor inhibitor (AAV)*
Orally administered, highly potent and selective inhibitor of C5aR1 (complement C5a receptor 1) for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA)-associated vasculitis (AAV).
VELPHORO® Sucroferric oxyhydroxide (Serum P control in CKD)
A non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on haemodialysis or peritoneal dialysis.
VELTASSA® Oral potassium binder (HK)
A non-absorbed, oral potassium binder for the treatment of hyperkalemia.
AUDENZ ®/CELLDEMIC® Adjuvanted Cell-based Monovalent Influenza A (H5N1) Vaccine
FOCLIVIA®/AFLUNOV® Adjuvanted Egg-based Influenza A (H5N1) Vaccine
Pre-pandemic, egg-based vaccine combined with CSL Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination), to protect against influenza A (H5N1) - the 'bird-flu' strain.
FLUAD® Trivalent Adjuvanted Egg-based Influenza Vaccine
FLUCELVAX® Trivalent Cell-based Influenza Vaccine
Seasonal cell culture-based, quadrivalent influenza vaccine offering protection against four different strains for use in children 6 months of age and older.
KOSTAIVE® sa-mRNA Vaccine (COVID)
Novel seasonal COVID-19 booster vaccine using self-amplifying platform. The technology offers the potential for higher efficacy and longer duration and breadth of protection at lower doses of mRNA.
*Indicates partnered projects